798
Views
45
CrossRef citations to date
0
Altmetric
Original Articles

Improving the Anticancer Activity of Curcumin Using Nanocurcumin Dispersion in Water

, &
Pages 1015-1022 | Received 21 Aug 2013, Accepted 03 May 2014, Published online: 28 Jul 2014

REFERENCES

  • Shishodia S, Sethi G, and Aggarwal BB: Curcumin: getting back to the roots. Ann NY Acad Sc 1056, 206–217, 2005.
  • Kim JM, Araki S, and Kim DJ: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation. Carcinogenesis 19, 81–85, 1998.
  • Chuang SE, Cheng AL, and Lin JK: Inhibition by curcumin of diethylnitrosamine induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle related proteins in rats. Food Chem Toxicol 38, 991–995, 2000.
  • Huang MT, Lou YR, and Xie JG: Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 19, 1697–1700, 1998.
  • Hecht SS, Kenney PM, and Wang M: Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137, 123–130, 1999.
  • Swamy MV, Citineni B, and Patlolla JM: Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr. Cancer 60, 81–89, 2008.
  • Odot J, Albert P, and Carlier A: In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111, 381–387, 2004.
  • Lo Tempio MM, Veena MS, and Steele HL: Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11, 6994–7002, 2005.
  • Dorai T, Cao YC, and Dorai B: Therapeutic potential of curcumin in human prostate cancer: III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47, 293–303, 2001.
  • Shankar S, Chen Q, and Sarva K: Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2, 10, 2007.
  • Abdullah Thani NA, Sallis B, Nuttall R, Schubert FR, Ahsan M, et al.: Induction of apoptosis and reduction of MMP gene expression in the U373 cell line by polyphenolics in Aronia melanocarpa and by curcumin. Oncol Rep 28, 1435–1442, 2012.
  • Guo X, Yin S, Dong,Y, Fan L, Ye M, et al.: Enhanced apoptotic effects by the combination of curcumin and methylseleninic acid: Potential role of Mcl-1 and FAK. Mol. Carcinog 52, 879–889, 2012.
  • Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, et al.: Curcumin induces G2/M arrest and apoptosis in cisplatin-resistanmt huan ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 6, 178–184, 2007.
  • Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, et al.: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4, 1035–1038, 2006.
  • Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847–6854, 2004.
  • Ireson CR, Jones DJ, and Orr S: Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev 11, 105–111, 2002.
  • Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894–1900, 2001.
  • Shoba G, Joy D, and Joseph T: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 64, 353–356, 1998.
  • Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, et al.: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14, 4491–4499.
  • Anand A, Kunnumakkara AB, Newman RA, and Aggarwal BB: Bioavailability of curcumin: problems and promises. Mol Pharm 4, 807–818, 2007.
  • Anand P, Thomas SG, Kunnumakkara AB, Sundarama C, Harikumar KB, et al.: Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76, 1590–1611.
  • Dhule SS, Penfornis P, Frazier T, Walker R, Feldman J, et al.:. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine 8, 440–451, 2012.
  • Mach CM, Mathew L, Mosley SA, Kurzrock R, and Smith JA: Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res 29, 1895–1899, 2009.
  • Li L, Bilal A, Mehta K, and Kurzrock R: Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6, 1276–1282, 2007.
  • Punfa W, Yodkeeree S, Pitchakarn P, Ampasavate C, and Limtrakul P: Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 33, 823–831, 2012.
  • Nair KL, Thulasidasan AK, Deepa G, Anto RJ, and Kumar GS: Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm 425, 44–52, 2012.
  • Bisht S, Feldmann G, Soni S, Ravi, Karikar C, et al.: Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotech 5, 3–21, 2007.
  • Kim TH, Jiang HH, Youn YS, Park CW, Tak KK, et al.: Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 403, 285–291, 2011.
  • Khalil NM, Nascimento TC, Casa DM, Dalmolin LF, Mattos AC, et al.: Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf B Biointerfaces 101C, 353–360, 2012.
  • Tsai YM, Chien CF, Lin LC, and Tsai TH: Curcumin and its nano-formulation: the kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharm 416, 331–338, 2011.
  • Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, and Atyabi F: Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine 6, 877–895, 2011.
  • Kakran M, Sahoo NG, Tan IL, and Li L: Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods. J Nanoparticle Res 14, 757, 2012.
  • Bhawana, Basniwal RK, Buttar HS, Jain VK, and Jain N: Curcumin nanoparticles: preparation, characterization and antimicrobial study. J Agric Food Chem 59, 2056–2061, 2011.
  • Cao J, Jia L, Zhou HM, Liu Y, and Zhong LF: Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol. Sci 91, 476–483, 2006.
  • Li H-Q, Jin L-J, Wu F-F, Li X-Y, You J-S, et al.: Effect of curcumin on proliferation, cell cycle, and caspases and MCF-7 cells. Afr J Pharm Pharmacol 6, 864–870, 2012.
  • Yen FL, Wu TH, Tzeng CW, Lin LT, and Lin CC: Curcumin nanoparticles improve the physicochemical properties of curcumin and effectively enhance its antioxidant and antihepatoma activities. J Agric Food Chem 58, 7376–7382, 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.